Cadrenal Therapeutics (CVKD) Projected to Post Quarterly Earnings on Thursday

Cadrenal Therapeutics (NASDAQ:CVKD) will likely be issuing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($1.55) per share for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:00 PM ET.

Cadrenal Therapeutics (NASDAQ:CVKD) last posted its quarterly earnings results on Monday, August 11th. The company reported ($1.87) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.27). On average, analysts expect Cadrenal Therapeutics to post $-8 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Cadrenal Therapeutics Stock Down 0.2%

NASDAQ CVKD opened at $12.86 on Thursday. Cadrenal Therapeutics has a 52 week low of $8.74 and a 52 week high of $22.90. The business’s fifty day simple moving average is $13.39 and its 200-day simple moving average is $13.47. The firm has a market cap of $26.36 million, a PE ratio of -1.45 and a beta of 0.96.

Insider Transactions at Cadrenal Therapeutics

In other Cadrenal Therapeutics news, CFO Matthew K. Szot sold 1,800 shares of the business’s stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $13.99, for a total transaction of $25,182.00. Following the sale, the chief financial officer directly owned 9,933 shares in the company, valued at $138,962.67. This represents a 15.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Quang X. Pham sold 1,800 shares of the business’s stock in a transaction dated Monday, October 13th. The stock was sold at an average price of $14.15, for a total transaction of $25,470.00. Following the sale, the chief executive officer owned 198,533 shares in the company, valued at $2,809,241.95. This trade represents a 0.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,644 shares of company stock worth $640,540 over the last quarter. Insiders own 26.09% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Cadrenal Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $32.00.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.